Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides

Pharmaceutical Research

Volumn 30, Issue 7, 2013, Pages 1813-1823

  Li, Jingwei ^a,b   Zhang, Chi ^a,b   Li, Jing ^a,b   Fan, Li ^a,b   Jiang, Xinguo ^a,b   Chen, Jun ^a,b   Pang, Zhiqing ^a,b   Zhang, Qizhi ^a  

^a FUDAN UNIVERSITY   (China)

^b School of Pharmacy   (China)

Author keywords

biodegradable nanoparticles; blood brain barrier (BBB); brain delivery; NAP

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-40]; CHOLINE ACETYLTRANSFERASE; MACROGOL; NANOPARTICLE; NEUROPEPTIDE; POLYGLACTIN; PROTEIN NAP; PROTEIN TGN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; ENZYME ACTIVITY; HIPPOCAMPUS; HISTOPATHOLOGY; IN VIVO STUDY; LEARNING DISORDER; LOW DRUG DOSE; MAZE TEST; MEMORY DISORDER; MOUSE; NANOEMULSION; NANOENCAPSULATION; NEUROPROTECTION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; SPATIAL LEARNING;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CHOLINE O-ACETYLTRANSFERASE; DRUG DELIVERY SYSTEMS; MALE; MEMORY DISORDERS; MICE; NANOPARTICLES; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYGLACTIN 910;

EID: 84878867162     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1025-4     Document Type: Article

References (22)

1. 2011 Alzheimer's disease facts and figures. Alzheimer's and Dementia: Alzheimer's Association; 2011;7(2):208-24.
2. De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A. 2005;102(10):3811-6. 2005-03-08. (Pubitemid 40360709)
3. Nagahara AH, Bernot T, Moseanko R, Brignolo L, Blesch A, Conner JM, et al. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol. 2009;215(1):153-9. 2009-01-01.
4. Wang ZL, Cheng SM, Ma MM, Ma YP, Yang JP, Xu GL, et al. Intranasally delivered bFGF enhances neurogenesis in adult rats following cerebral ischemia. Neurosci Lett. 2008;446(1):30-5. 2008-11-28.
5. Lobner D, Ali C. Mechanisms of bFGF and NT-4 potentiation of necrotic neuronal death. Brain Res. 2002;954(1):42-50. 2002-11-01. (Pubitemid 35223439)
6. Gozes I. Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacol Ther. 2007;114(2):146-54. 2007-05-01. (Pubitemid 46578333)
7. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res. 2003;144(1):83-90. 2003-08-12. (Pubitemid 36897699)
8. Poggi SH, Goodwin K, Hill JM, Brenneman DE, Tendi E, Schinelli S, et al. The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol. 2003;189(3):790-3. 2003-09-01. (Pubitemid 37194107)
9. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem. 1999;72(3):1283-93. 1999-03-01. (Pubitemid 29085045)
10. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, et al. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther. 2001;296(1):57-63. 2001-01-01. (Pubitemid 32015060)
11. Zemlyak I, Manley N, Sapolsky R, Gozes I. NAP protects hippocampal neurons against multiple toxins. Peptides. 2007;28(10):2004-8. 2007-10-01. (Pubitemid 47419114)
12. Alcalay RN, Giladi E, Pick CG, Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett. 2004;361(1-3):128-31. 2004-05-06. (Pubitemid 38609233)
13. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem. 2006;98(3):973-84. 2006-08-01. (Pubitemid 44051296)
14. Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S, Brenneman DE. NAP accelerates the performance of normal rats in the water maze. J Mol Neurosci. 2002;19(1-2):167-70. 2002-08-01. (Pubitemid 35013351)
15. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). Cns Drug Rev. 2005;11(4):353-68. 2005-06-01.
16. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci. 2007;31(2):165-70. 2007-01-20. (Pubitemid 46742300)
17. Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials. 2011;32(21):4943-50. 2011-07-01.
18. Sureda FX, Gutierrez-Cuesta J, Romeu M, Mulero M, Canudas AM, Camins A, et al. Changes in oxidative stress parameters and neurodegeneration markers in the brain of the senescence-accelerated mice SAMP-8. Exp Gerontol. 2006;41(4):360-7. 2006-04-01.
19. de Freitas RM. Lipoic Acid increases hippocampal choline acetyltransferase and acetylcholinesterase activities and improvement memory in epileptic rats. Neurochem Res. 2010;35(1):162-70. 2010-01-01.
20. Park D, Lee HJ, Joo SS, Bae DK, Yang G, Yang YH, et al. Human neural stem cells over-expressing choline acetyltransferase restore cognition in rat model of cognitive dysfunction. Exp Neurol. 2012;234(2):521-6. 2012-04-01.
21. Wang H, He J, Zhang R, Zhu S, Wang J, Kong L, et al. Sensorimotor gating and memory deficits in an APP/PS1 double transgenic mouse model of Alzheimer's disease. Behav Brain Res. 2012;233(1):237-43. 2012-07-15.
22. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457(7233):1128-32. 2009-02-26.